$NTRA

RABINOWITZ DANIEL sold $485K of NTRA

RABINOWITZ DANIEL (SEC. AND CHIEF LEGAL OFFICER) sold 1,887 shares of Natera, Inc. (NTRA) at an average of $257.08 ($254.07–$260.49, $0.49M total) across 2 trades over 2026-07-27 to 2026-07-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RABINOWITZ DANIEL
Published Jul 30, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 2:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not change Natera’s business outlook based on the information provided.

02

Market read

Insider selling under a 10b5-1 plan is generally low-signal; any trading impact is likely limited unless corroborated by other negative catalysts.

03

What to watch

Traders should check whether there were concurrent insider buys/sales by other executives and whether the sale size is unusual relative to prior Form 4 activity.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-07-29, covering sales on 2026-07-27 to 2026-07-28.

Background

The article is a primary-source SEC Form 4 insider transaction for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows Daniel Rabinowitz, Chief Legal Officer, sold 1,887 shares in open-market trades under a 10b5-1 plan at $254.07 to $260.49.

Expected impact

Likely limited, short-lived impact unless paired with other negative company news.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by an officer; it does not provide new operational, financial, or regulatory information.

Market effects

Minimal; insider sale in a single biotech/health-tech name does not reset sector fundamentals.

Minimal; US-listed filing with no broader macro/regional catalyst.

Minimal; no international transaction or regulatory action described.

Counterpoint

Because the trades are explicitly under a pre-arranged 10b5-1 plan, the sale may reflect diversification or liquidity needs rather than a bearish view.

Key entities

  • Natera, Inc.

    US-listed company whose officer insider sale is disclosed via SEC Form 4.

  • Daniel Rabinowitz

    Chief Legal Officer who sold shares in open-market transactions under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Jim Cramer Calls Natera (NTRA) “a Promising Story”

Natera (NTRA) reported Q2 revenue of $752.8M, up 37.7% YoY, and raised its 2026 revenue forecast. Jim Cramer called it a promising precision medicine platform but advised waiting for a pullback due to valuation concerns. The company faces competition and regulatory risks, with a net loss of $67M in Q2.

$MRNAHighAI 8/10

Why Moderna's Cancer Vaccine Matters To Investors

Moderna (MRNA) and Merck (MRK) reported successful late-stage trial results for a personalized mRNA cancer vaccine targeting melanoma, reducing recurrence risk by 49%. The treatment relies on technologies from Illumina (ILMN), Danaher (DHR), and others. Moderna's stock surged 176.97% on the news, highlighting the shift toward individualized therapies in oncology.

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.